270 related articles for article (PubMed ID: 32846644)
21. Targeting the NLRP3 Inflammasome in Severe COVID-19.
Freeman TL; Swartz TH
Front Immunol; 2020; 11():1518. PubMed ID: 32655582
[TBL] [Abstract][Full Text] [Related]
22. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes.
Moreno-Eutimio MA; López-Macías C; Pastelin-Palacios R
Microbes Infect; 2020; 22(4-5):226-229. PubMed ID: 32361001
[TBL] [Abstract][Full Text] [Related]
23. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
Schijns V; Lavelle EC
Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
[TBL] [Abstract][Full Text] [Related]
24. Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
O'Brien TR; Thomas DL; Jackson SS; Prokunina-Olsson L; Donnelly RP; Hartmann R
Clin Infect Dis; 2020 Sep; 71(6):1410-1412. PubMed ID: 32301957
[No Abstract] [Full Text] [Related]
25. Potential therapeutic effects of Resveratrol against SARS-CoV-2.
Ramdani LH; Bachari K
Acta Virol; 2020; 64(3):276-280. PubMed ID: 32985211
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
Addeo A; Obeid M; Friedlaender A
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32434788
[TBL] [Abstract][Full Text] [Related]
27. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
28. Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment.
Szeto MD; Maghfour J; Sivesind TE; Anderson J; Olayinka JT; Mamo A; Runion TM; Dellavalle RP
Dermatology; 2021; 237(6):847-856. PubMed ID: 34511591
[TBL] [Abstract][Full Text] [Related]
29. Dupilumab and COVID-19: What should we expect?
Patruno C; Stingeni L; Fabbrocini G; Hansel K; Napolitano M
Dermatol Ther; 2020 Jul; 33(4):e13502. PubMed ID: 32362061
[TBL] [Abstract][Full Text] [Related]
30. More questions than answers, and a way ahead.
La Manna G
G Ital Nefrol; 2020 Apr; 37(2):. PubMed ID: 32281753
[No Abstract] [Full Text] [Related]
31. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
Sun J; Chen Y; Fan X; Wang X; Han Q; Liu Z
Postgrad Med; 2020 Sep; 132(7):604-613. PubMed ID: 32496926
[TBL] [Abstract][Full Text] [Related]
32. Role of Toll-like receptors in the pathogenesis of COVID-19.
Khanmohammadi S; Rezaei N
J Med Virol; 2021 May; 93(5):2735-2739. PubMed ID: 33506952
[TBL] [Abstract][Full Text] [Related]
33. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.
Remy KE; Mazer M; Striker DA; Ellebedy AH; Walton AH; Unsinger J; Blood TM; Mudd PA; Yi DJ; Mannion DA; Osborne DF; Martin RS; Anand NJ; Bosanquet JP; Blood J; Drewry AM; Caldwell CC; Turnbull IR; Brakenridge SC; Moldwawer LL; Hotchkiss RS
JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32687484
[TBL] [Abstract][Full Text] [Related]
34. Surviving COVID-19: A disease tolerance perspective.
Ayres JS
Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
[No Abstract] [Full Text] [Related]
35. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang Y; Zhong Y; Pan L; Dong J
Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
[TBL] [Abstract][Full Text] [Related]
36. Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes.
Korakas E; Ikonomidis I; Kousathana F; Balampanis K; Kountouri A; Raptis A; Palaiodimou L; Kokkinos A; Lambadiari V
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E105-E109. PubMed ID: 32459524
[TBL] [Abstract][Full Text] [Related]
37. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?
Casillo GM; Mansour AA; Raucci F; Saviano A; Mascolo N; Iqbal AJ; Maione F
Pharmacol Res; 2020 Jun; 156():104791. PubMed ID: 32302707
[TBL] [Abstract][Full Text] [Related]
38. Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response.
Cunha LL; Perazzio SF; Azzi J; Cravedi P; Riella LV
Front Immunol; 2020; 11():1748. PubMed ID: 32849623
[TBL] [Abstract][Full Text] [Related]
39. The microbial coinfection in COVID-19.
Chen X; Liao B; Cheng L; Peng X; Xu X; Li Y; Hu T; Li J; Zhou X; Ren B
Appl Microbiol Biotechnol; 2020 Sep; 104(18):7777-7785. PubMed ID: 32780290
[TBL] [Abstract][Full Text] [Related]
40. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
